ZVS101e in Patients With Bietti's Crystalline Dystrophy (ZVS101e-BCD)

Inclusion Criteria:

1. Voluntarily participate in the research and sign the informed consent form, and be willing to complete the entire process according to the protocol requirements;
2. Clinically diagnosed with Bietti's Crystalline Dystrophy (BCD), age ≥ 18 years;
3. Confirmed by genetic testing to carry homozygous or compound heterozygous mutations in CYP4V2, and not complicated with other ophthalmic genetic diseases;
4. Target eye BCVA ≤ 60 ETDRS letters.

Exclusion Criteria:

Subjects will be excluded if they meet any 1 of the following exclusion criteria:

1. The target eye currently has or has a history of macular lesions; suffers from ocular diseases that may hinder surgery or interfere with the interpretation of study endpoints;
2. The target eye has previously undergone retinal reattachment surgery, vitrectomy, or any intraocular surgery within 3 months before enrollment;
3. Within 1 month before enrollment, suffered from viral infectious diseases that may affect the evaluation of the efficacy and safety of the investigational drug, or received antiviral vaccines;
4. The target eye has previously received gene therapy or stem cell therapy for BCD or other ocular diseases;
5. Known allergy to the drugs planned for use in the study;
6. The laboratory abnormalities are considered clinically significant;
7. Pregnant or lactating females.